FBIO 241220 5.00P (FBIO241220P5000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

FBIO241220P5000

Watchlist

0.00
0.000.00%

15min DelayTrading Nov 25 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Cuts Target Price to $4
Moomoo NewsNov 19 03:36 ET · Ratings
Fortress Biotech Price Target Lowered to $4 From $5 at Alliance Global Partners
TipRanksNov 18 10:15 ET
HC Wainwright & Co. Maintains Buy on Fortress Biotech, Raises Price Target to $26
BenzingaNov 18 07:45 ET · Ratings
Fortress Biotech Analyst Ratings
BenzingaNov 18 07:43 ET · Ratings
Fortress Biotech GAAP EPS of -$0.76 Misses by $0.17, Revenue of $14.62M
Seeking AlphaNov 14 17:33 ET
10-Q: Q3 2024 Earnings Report
SECNov 14 16:46 ET · Announcements

Comments

Clintzilla

1 hour ago

$Fortress Biotech (FBIO.US)$ over here, slow and low volume

Trytosaveabit

Oct 28 05:47

Heads-up / Reminder

$Fortress Biotech (FBIO.US)$ On FDA PDUFA Calendar for BLA of DFD-29 for treatment of lesions and erythema of rosacea in adults on 11/04/2024

Clintzilla

Oct 23 06:43

$Fortress Biotech (FBIO.US)$ should pump a little off MBIO if it gets running regular hours by Tutes

Clintzilla

Sep 19 06:49

$Fortress Biotech (FBIO.US)$ TBIO made me look.. ;) almost time.. grab a starter if your patient instead of chasing 3-4 later on

Trytosaveabit

Jul 19 07:12

Update

$Fortress Biotech (FBIO.US)$ Fortress Biotech's Urica Therapeutics Entered Into An APA Royalty Agreement, Urica Sold The Rights To Its URAT1 Inhibitor Product Candidate In Development For The Treatment Of Gout, Dotinurad, And Related Intellectual Property, Licenses And Agreements To Crystalys Therapeutics In Return For Common Stock Equal To 35% Of Crystalys' Outstanding Equity
- SEC Filing